Hypothyroidism: Underactive Thyroid
Hypothyroidism occurs when the thyroid gland fails to produce sufficient thyroid hormone to meet the body's metabolic demands, affecting an estimated 4.6% of the U.S. population aged 12 and older according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This page covers the definition and classification of hypothyroidism, the physiological mechanism driving hormone deficiency, the clinical scenarios in which it most commonly presents, and the decision boundaries that distinguish subclinical from overt disease. Understanding where hypothyroidism fits within the broader endocrinology landscape is essential context for interpreting thyroid function test results and management thresholds.
Definition and scope
Hypothyroidism is defined as an insufficient secretion of thyroxine (T4) and triiodothyronine (T3) from the thyroid gland, resulting in elevated serum thyroid-stimulating hormone (TSH) when the defect originates at the thyroid level. The American Thyroid Association (ATA) classifies the condition along two primary axes: etiology (primary vs. central) and severity (subclinical vs. overt).
Primary hypothyroidism arises from intrinsic thyroid gland failure. The pituitary responds by increasing TSH secretion, making elevated TSH the hallmark biochemical finding. Primary hypothyroidism accounts for the large majority of diagnosed cases in the United States, with Hashimoto's thyroiditis (autoimmune thyroiditis) representing the single most common cause in iodine-sufficient populations.
Central hypothyroidism — encompassing both secondary (pituitary) and tertiary (hypothalamic) forms — results from inadequate TSH or thyrotropin-releasing hormone (TRH) secretion. TSH may be low, normal, or minimally elevated despite low free T4. The National Organization for Rare Disorders (NORD) notes that central hypothyroidism is substantially less common than primary forms and requires distinct diagnostic interpretation.
Additional recognized subtypes include:
- Congenital hypothyroidism — present at birth, detectable via newborn screening programs mandated across all 50 U.S. states under public health frameworks overseen by state health departments in coordination with the Health Resources and Services Administration (HRSA).
- Iatrogenic hypothyroidism — induced by thyroidectomy, radioactive iodine ablation, or medications such as amiodarone and lithium.
- Transient hypothyroidism — occurring in the context of postpartum thyroiditis or subacute thyroiditis, where thyroid function typically normalizes within 12 months.
- Subclinical hypothyroidism — elevated TSH with free T4 within the reference range; symptomatic status and TSH magnitude determine management decisions.
How it works
The thyroid gland produces T4 and T3 under stimulation by TSH, which is secreted by the anterior pituitary in response to hypothalamic TRH. Approximately 80% of circulating T3 — the biologically active form — is generated by peripheral deiodination of T4 rather than direct thyroid secretion, as noted by the NIDDK.
When thyroid hormone levels fall, the hypothalamic-pituitary-thyroid (HPT) axis responds through negative feedback: reduced T4/T3 removes inhibitory signaling from the pituitary, driving TSH upward. In Hashimoto's thyroiditis, lymphocytic infiltration and anti-thyroid peroxidase (anti-TPO) antibodies progressively destroy follicular architecture, reducing the gland's secretory capacity over months to years.
Thyroid hormones regulate basal metabolic rate, cardiac output, lipid metabolism, gastrointestinal motility, bone turnover, and neurodevelopment. Deficiency therefore produces a multisystem syndrome: slowing of metabolic processes manifests as weight gain, bradycardia, constipation, cold intolerance, dry skin, and cognitive slowing. In severe or prolonged deficiency, myxedematous changes — accumulation of glycosaminoglycans in subcutaneous tissue — and, at the extreme end, myxedema coma (a life-threatening emergency) can occur.
Measurement of thyroid function tests — specifically TSH and free T4 — forms the biochemical foundation of diagnosis, with the ATA and the American Association of Clinical Endocrinology (AACE) publishing reference ranges and interpretation guidance used by clinical laboratories nationally.
Common scenarios
Hypothyroidism surfaces across distinct clinical populations and settings:
Autoimmune thyroiditis in adults — Hashimoto's thyroiditis predominantly affects women, with a female-to-male ratio of approximately 7:1 per NIDDK data. Onset is typically insidious, with thyroid function declining over years before overt deficiency is detected on routine screening.
Post-treatment hypothyroidism — Patients who have undergone thyroid surgery or radioactive iodine therapy for hyperthyroidism or thyroid cancer frequently require lifelong thyroid hormone replacement. This is an expected and anticipated outcome, not a complication per se.
Pregnancy — Thyroid hormone demands increase by approximately 30–50% during gestation. Uncontrolled hypothyroidism during pregnancy is associated with adverse fetal neurodevelopmental outcomes and obstetric complications, making pregnancy and endocrine conditions a high-priority management context. The Endocrine Society and ATA publish specific TSH target ranges for each trimester.
Medication-induced hypothyroidism — Amiodarone, lithium, interferon-alpha, and certain tyrosine kinase inhibitors used in oncology carry recognized thyroid-suppressive effects. Monitoring protocols are addressed within the regulatory context for endocrinology as they intersect with drug labeling requirements under FDA oversight.
Pediatric presentation — Congenital hypothyroidism, if untreated in the first weeks of life, causes irreversible intellectual disability. Newborn TSH screening programs have dramatically reduced this outcome; pediatric endocrinology specialists manage congenital and acquired juvenile cases.
Decision boundaries
Distinguishing subclinical from overt hypothyroidism — and determining when to initiate treatment — constitutes the central clinical decision problem:
| Parameter | Subclinical Hypothyroidism | Overt Hypothyroidism |
|---|---|---|
| TSH | Elevated (typically 4.5–10 mIU/L) | Markedly elevated (>10 mIU/L common) |
| Free T4 | Within reference range | Below reference range |
| Symptoms | Absent or minimal | Present, often multisystem |
| Treatment threshold | Individualized (ATA/AACE guidelines) | Initiate replacement |
The ATA's 2014 guidelines, which remain the principal reference document, stratify subclinical hypothyroidism management by TSH level, symptom burden, age, cardiovascular risk, and pregnancy status. TSH above 10 mIU/L generally warrants treatment regardless of symptoms; TSH between 4.5 and 10 mIU/L in asymptomatic, non-pregnant adults without cardiovascular disease may be managed with watchful waiting and repeat testing at 6–12 month intervals.
Central hypothyroidism requires a distinct diagnostic boundary: TSH-based screening thresholds do not apply because TSH secretion itself is impaired. Free T4 measurement becomes the primary parameter, and evaluation should include pituitary hormone panels and MRI to identify structural or functional pituitary pathology.
Myxedema coma represents the extreme severity boundary — a medical emergency characterized by altered consciousness, hypothermia, hypoventilation, and cardiovascular compromise. It falls outside outpatient management frameworks and requires inpatient intensive intervention with intravenous thyroid hormone replacement.
References
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — Hypothyroidism
- American Thyroid Association (ATA)
- American Association of Clinical Endocrinology (AACE)
- The Endocrine Society
- National Organization for Rare Disorders (NORD) — Central Hypothyroidism
- Health Resources and Services Administration (HRSA) — Newborn Screening
- U.S. Food and Drug Administration (FDA) — Drug Labeling Resources
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)